13F Holdings
中文EN

DSGN Design Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1807120 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-9.8%
TTM EPS YoY-0.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-36.9%
ROA-34.6%
ROIC (approx.)-35.0%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets6.7%
Debt / equity0.00x
Current ratio16.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0———
R&D expense$59.13M$44.35M$57.06M$48.61M$24.78M
SG&A expense$20.34M$18.03M$21.13M$18.98M$11.05M
Operating income-$79.47M-$62.38M-$78.19M-$67.59M-$35.83M
Income tax$0$0———
Net income-$69.79M-$49.59M-$66.86M-$63.31M-$35.53M
EBITDA-$78.84M-$61.79M-$77.65M-$67.19M-$35.70M
EPS (basic)-1.22-0.88-1.19-1.14-0.77
EPS (diluted)-1.22-0.88-1.19-1.14-0.77
Weighted avg. shares (diluted)57.33M56.59M55.98M55.71M45.94M
Balance sheet
Cash & equivalents$16.86M$22.56M$21.20M$26.50M$298.57M
Short-term investments$202.99M$222.91M$260.60M$303.89M$85.50M
Current assets$223.78M$248.04M$284.58M$335.12M$385.44M
PP&E, net$981,000$1.41M$1.69M$1.95M$1.51M
Total assets$226.20M$252.09M$289.64M$341.14M$390.56M
Current liabilities$13.05M$8.46M$9.62M$10.78M$5.28M
Total liabilities$13.70M$10.00M$11.96M$13.83M$8.43M
Shareholders' equity$212.50M$242.10M$277.69M$327.31M$382.13M
Shares outstanding60.40M56.75M56.47M55.90M55.44M
Cash flow statement
Operating cash flow-$54.36M-$43.10M-$58.56M-$51.32M-$29.38M
Capital expenditure$193,000$340,000$256,000$918,000$1.54M
Free cash flow-$54.55M-$43.45M-$58.82M-$52.23M-$30.91M
Investing cash flow$22.91M$43.95M$52.54M-$220.99M-$53.64M
Financing cash flow$25.74M$513,000$724,000$235,000$379.21M
Depreciation & amortization$622,000$596,000$537,000$406,000$129,000
Stock-based compensation$14.55M$13.07M$13.09M$10.93M$4.69M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.